AbstractMinimizing the transfusion burden is one of the primary clinical goals for most patients with myelodysplastic syndromes (MDS), which are incurable hematopoietic stem cell neoplasms. In some ...
Abstract:. In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of ...
Abstract. Results from the DRUP trial suggest that off-label targeted cancer therapies produce meaningful benefit primarily in tumors with well-validated biomarkers, such as MSI-H, echoing findings ...
Abstract:. Under the Trump Administration’s proposed budget for fiscal year 2027, and if enacted, the NIH would receive $41.2 billion, down from $47.22 in fiscal year 2026, and NCI would receive ...
Cancer Res (2026) 86 (7_Supplement): 5810.
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
You do not currently have access to this content.
Memorial Sloan Kettering Cancer Center, New York, NY.
Cancer Res (2025) 85 (8_Supplement_2): ND11.
Tianjin Medical Univ. Cancer Inst. & Hospital, Tianjin, China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results